RecruitingNCT06516406
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Enrollment
- 1055 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2032
Study locations (26)
- Azienda Ospedaliera Annunziata, Cosenza, Calabria, Italy
- Grande Ospedale Metropolitano "Bianchi Melacrino Morelli", Reggio Calabria, Calabria, Italy
- Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo, Naples, Campania, Italy
- IRCCS Policlinico Sant'Orsola, Bologna, Emilia-Romagna, Italy
- Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna, Ferrara, Emilia-Romagna, Italy
- Azienda Ospedaliero-Universitaria di Parma, Parma, Emilia-Romagna, Italy
- AUSL di Piacenza - Palazzine Medicine Specialistiche, Piacenza, Emilia-Romagna, Italy
- Dipartimento Oncoematologico - AUSL della Romagna, Ravenna, Emilia-Romagna, Italy
- Ospedale Infermi di Rimini, Rimini, Emilia-Romagna, Italy
- A.O.U. Integrata di Udine, Udine, Friuli Venezia Giulia, Italy
- A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza", Rome, Lazio, Italy
- Ospedale S. Eugenio, Rome, Lazio, Italy
- Ospedale Belcolle, Viterbo, Lazio, Italy
- IRCCS Azienda Ospedaliera Universitaria "San Martino" - IST, Genoa, Liguria, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06516406 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.